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Abstract
Placental lactogen (PL) induced serotonergic signaling is essential for gestational b-cell mass expansion. We have previously
shown that intact Epidermal growth factor –receptor (EGFR) function is a crucial component of this pathway. We now
explored more specifically the link between EGFR and pregnancy-induced b-cell mass compensation. Islets were isolated
from wild-type and b-cell-specific EGFR-dominant negative mice (E1-DN), stimulated with PL and analyzed for b-cell
proliferation and expression of genes involved in gestational b-cell growth. b-cell mass dynamics were analyzed both with
traditional morphometrical methods and three-dimensional optical projection tomography (OPT) of whole-mount insulin-
stained pancreata. Insulin-positive volume analyzed with OPT increased 1.4-fold at gestational day 18.5 (GD18.5) when
compared to non-pregnant mice. Number of islets peaked by GD13.5 (680 vs 1134 islets per pancreas, non-pregnant vs.
GD13.5). PL stimulated beta cell proliferation in the wild-type islets, whereas the proliferative response was absent in the E1-
DN mouse islets. Serotonin synthesizing enzymes were upregulated similarly in both the wild-type and E1-DN mice.
However, while survivin (Birc5) mRNA was upregulated 5.5-fold during pregnancy in the wild-type islets, no change was
seen in the E1-DN pregnant islets. PL induced survivin expression also in isolated islets and this was blocked by EGFR
inhibitor gefitinib, mTOR inhibitor rapamycin and MEK inhibitor PD0325901. Our 3D-volumetric analysis of b-cell mass
expansion during murine pregnancy revealed that islet number increases during pregnancy. In addition, our results suggest
that EGFR signaling is required for lactogen-induced survivin expression via MAPK and mTOR pathways.
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Introduction
Pregnancy is one of the most robust physiological stimuli of b-
cell mass expansion in the adult pancreas. This compensates for
the rise in insulin demand, which is due to reduced insulin
sensitivity in target tissues. In pregnant rodents, b-cell proliferation
increases dramatically, with a peak occurring after mid gestation
and returning to postpartum levels after day 18.5 [1,2]. The most
important factors leading to b-cell mass expansion during
pregnancy are the lactogenic hormones prolactin (Prl) and
placental lactogen (PL) which both activate the prolactin receptor
(Prl-R) [3]. The peak in b-cell proliferation coincides with the peak
of PL levels [1]. Ligand-binding to the Prl-R leads to activation of
the janus kinase 2 (JAK2)-signal transducer and STAT5 pathways
[4]. In addition, Prl-R can activate MAPK and PI3K pathways
[5]. Several studies have explored the gene network changes in
islets during pregnancy [6–8]. Placental lactogen controls b-cell
mass expansion at multiple levels, including upregulation of
serotonin synthesis by b-cells [7,9], induction of the transcription
factor FoxM1 [10], downregulation of Menin [11], and upregula-
tion of survivin (Birc5) [6].
Many studies have shown that increased proliferation of b-cells
is the key mechanism explaining the expansion of b-cell mass
during pregnancy [2,10,12,13]. It has been suggested that the
number of islets remains constant whereas individual islets grow in
size [14]. On the other hand, some studies report that in addition
to increased proliferation, the number of islets increases during
pregnancy [3]. Supporting this, a lineage-tracing experiment by
Abouna et al. shows that some non-b-cells differentiate into
insulin-producing cells during pregnancy suggesting islet neogen-
esis [15]. Furthermore, autopsy studies of human maternal
pancreata during pregnancy have shown an increase in the
number of small islets rather than increased b-cell proliferation
[16].
The measurement of b-cell mass and islet number has so far
been mostly based on approximation from two-dimensional
models based on insulin immunohistochemistry. Optical projec-
tion tomography (OPT) was recently introduced for reliable
visualization of b-cell mass in the intact pancreas [17,18]. This
method allows three-dimensional imaging of insulin-positive islets
from the whole pancreas and quantification of insulin-positive
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volume as well as islet number. OPT has not been previously used
to measure pregnancy-induced islet mass expansion.
We have previously shown that EGFR signaling is important in
pancreatic development, survival and postnatal b-cell prolifera-
tion, particularly during pregnancy [12,19,20]. In this study we
investigated in more detail the molecular mechanisms through
which EGFR participates in gestational b-cell compensation and
have applied OPT for the 3D-analysis of islet number and b-cell
mass during pregnancy.
Materials and Methods
Animals
The E1-DN mice were generated as previously described [19].
Briefly, the E1-DN transgene consists of the mouse Pdx1
promoter, followed by a betaglobin second intron, the human
kinase-deficient EGFR cDNA with a myc-tag and a growth
hormone polyA tail. All mice were maintained in FVB
background, housed on a 12-h light-dark cycle and fed ad libitum
without restriction to physical activity. The study protocol was
approved by The National Animal Experiment Board of Finland
(permit number ESAVI-2010-09238/Ym-23). Wild-type controls
were derived from litters or non-related litters. For the pregnancy
experiment, E1-DN and wild-type mice were mated with male
FVB mice. Mating was confirmed by the presence of a vaginal
plug on the next morning, designated as day 0.5 of gestation. Mice
were killed with CO2 .70% followed by cervical dislocation and
samples collected on days 13.5, 14.5 and 18.5 of pregnancy.
Immunohistochemistry
The paraffin sections were stained as previously described [12].
Antibodies used were guinea pig anti-swine insulin (Dako
Cytomation, Glostrup, Denmark), mouse anti-BrdU (Dako
Cytomation), rabbit anti-survivin (Cell Signalling Technology),
rabbit anti-C-peptide (Cell Signalling Technology, Danvers, MA,
USA) and rabbit anti-ChromograninA (Dako Cytomation).
Specificity of the survivin antiserum was confirmed by preabsorb-
tion with a survivin blocking peptide for 30 min (Cell Signalling
Technology).
For light microscopy stainings the sections were incubated for
30 min at room temperature with a biotinylated secondary
antibody (Zymed Laboratories, South San Francisco, CA, USA),
rinsed and incubated with peroxidase-conjugated streptavidin
(Zymed Laboratories). The sections were finally developed with 3-
amino-9-ethyl-carbazole substrate (Thermo Scientific). For fluo-
rescence microscopy, the secondary antibodies used were goat
anti-guinea pig IgG (Alexa, A11076, Invitrogen, Paisley, UK),
donkey anti-rabbit IgG (Alexa, A21206, Invitrogen) and donkey
anti-mouse IgG (Alexa, A21202, Invitrogen). Nuclear staining was
performed with DAPI (Vectashield with DAPI, Vector Laborato-
ries, Burlingame, CA, USA).
Organ preparation and OPT scanning
The pancreata of FVB control and pregnant mice were
processed as described by Alanentalo et al. [17]. Shortly, the
pancreata were fixed in 4% PFA for 4 h, dehydrated in methanol,
quenched in MeOH: DMSO: H2O2 (2:1:3), followed by rehydra-
tion to TBST and incubations with guinea pig anti-swine insulin
(DakoCytomation, Glostrup, Denmark) and goat anti-guinea pig
IgG (Alexa, A11076, Invitrogen). The stained pancreata were
mounted in low melting agarose, followed by dehydration in
methanol and clearing with BABB. Bioptonics 3001 OPT scanner
(Bioptonics) was used for the scanning of the samples, with exiter
D560/40 nm and emitter 610 nmLP or exiter 425/40 nm and
emitter 475 nmLP when visualizing Alexa 594 and 488 respec-
tively. Scanning settings (identical for all specimen) were: rotation
degree 0,9 um; pixel size 18,23 um; resolution 102461024 pixels;
exposure time was set manually depending of the intensity of the
fluorescence. All samples were scanned with the same zoom. OPT
sample reconstructions were made with NRecon v1.6.3.3 (Sky-
Scan). Isosurface reconstructions were generated using Imaris v
7.6.3 (Bitplane). Islet volumes were segmented using the ‘‘back-
ground subtraction (local contrast)’’ thresholding option and the
intensity threshold was set manually for each pancreas.
2D Beta cell mass and islet size distribution analysis
For the morphometrical beta cell mass quantification, pancreata
were either fixed directly in 4% PFA o/n and processed with
routine methods or fixed and processed as described above for the
OPT analysis and after OPT imaging washed in methanol,
rehydrated in ethanol series and incubated in 0.29 M sucrose to
remove the agarose followed by routine processing to generate
paraffin blocks. The pancreatic paraffin blocks were sectioned and
five sections, one per 100–150 mm intervals, were analysed. These
sections were stained for insulin, counterstained with haematoxylin
and morphometrically analysed directly under light microscopy
using the Image-Pro Analyser 6.0 software (Media Cybernetics,
Bethesda, MD). The beta cell mass was calculated by multiplying
the relative cross-sectional area of the insulin-positive area per
total pancreatic tissue area by the weight of the pancreas. Islets
were classified into small ,12076 mm2, medium 12076–
35033 mm2 and large islets .35033 mm2 and the amount of islets
was calculated as relative to total pancreatic area and further
corrected by multiplying with the pancreatic weight.
Islet isolation
Islets from wild-type and E1-DN control and pregnant mice
were isolated by collagenase digestion (Collagenase P; Roche
diagnostics, Mannheim, Germany) followed by handpicking under
a stereomicroscope. Directly after isolation the islets were lysed in
the RNA extraction buffer (NucleoSpin RNAII kit, Macherey-
Nagel, Du¨ren, Germany). For proliferation analysis and PL
stimulation experiments islets were cultured as described below.
Quantitative RT-PCR
Total RNA from wild-type and E1-DN islets was isolated using
the NucleoSpin RNAII kit (Macherey-Nagel) without on-column
DNase treatment. DNase treatment was done separately followed
by RNA purification with NucleoSpin RNA CleanUp XS kit
according to manufacturer’s instructions (Macherey-Nagel). RNA
quality was controlled with NanoDrop 1000 spectrophotometer
(Thermo Scientific, Wilmington, DE, USA). cDNA was synthe-
sized from approximately 70 ng of islet RNA. Real-time PCR was
done with SYBR Green JumpStart Taq ReadyMix for Quanti-
tative PCR (Sigma-Aldrich, ST Louis, MO, USA) with Corbett
Rotor-Gene 6000 instrument (Qiagen, Hilden, Germany). The
reactions were prepared with a Corbett CAS-1200 liquid handling
system. All reactions were performed in duplicates on at least three
biological replicates. The median CT values were used for DDCT
analysis [21] with housekeeping gene Cyclophilin G as endoge-
nous control. Exogenous positive control was used as a calibrator
for all the real-time PCRs. Primer sequences are presented in
Table S1. Human and endogenous mouse transcripts were
distinguished with species-specific primers (Table S1). DNA
extraction and genotyping of the mice were done as previously
described by Miettinen et al [19].
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Cell culture
In proliferation experiments mouse islets were cultured in
RPMI supplemented with Glutamax, penicillin (100 IU/ml),
streptomycin (100 IU/ml) and 10% fetal calf serum either with
or without PL 500 ng/ml (Affiland, Lie`ge, Belgium) for 96 h.
BrdU 30 mg/ml (Sigma-Aldrich) was added for the last 48 h. For
RNA isolation the islets were cultured in RPMI supplemented
with Glutamax, penicillin (100 IU/ml), streptomycin (100 IU/ml),
10% fetal calf serum and stimulated with 500 ng/ml PL (Affiland),
2 mM gefitinib (Selleckchem, Houston, TX, USA), 10 nM
rapamycin (Selleckchem) or 0,5 mM MEK inhibitor PD0325901
(Selleckchem) for 96 h. All inhibitors were dissolved in DMSO and
DMSO 0,02% was also added to the control and PL only media.
After stimulation the islets were lysed in the RNA extraction buffer
(NucleoSpin RNAII kit).
Statistical analysis
All data are presented as means 6SEM from at least three
independent experiments. Significances of the differences between
three or more groups were calculated with one-way ANOVA
followed by Tukey’s test, using Graph Pad Prism 6 software.
Results
b-cell mass of E1-DN mice does not grow during
pregnancy.
To investigate the molecular mechanism by which EGFR
signaling participates in beta cell proliferation during pregnancy,
E1-DN mice were used as a model. These mice express a mutant
kinase-negative EGFR under the Pdx1 promoter, which leads to
approximately 40% reduction in EGFR phosphorylation upon
EGF stimulation in homozygous animals. In heterozygous
animals, which were used in these experiments, the phenotype is
milder and the mice are normoglycemic under normal physiolog-
ical situations [12].
During pregnancy the b-cell mass of wild-type mice increased
by 50% (from 1,2 to 1,8 mg, p,0.01). In contrast, the E1-DN
mice did not show any increase in b-cell mass while pregnant (0,5
vs 0,6 mg, ns) (Fig 1A). We have previously shown that in vivo the
proliferation of E1-DN b-cells does not increase during pregnancy
[12]. However, it was unclear whether the reduced proliferation is
due to a defective effect of PL/Prl action on beta cells or due to a
reduced proliferative effect of the EGFR ligands. To elucidate this,
we isolated islets from wild-type and E1-DN virgin mice,
stimulated them in vitro for 96 h with PL and analyzed b-cell
proliferation rate. Indeed, we could detect an increase in the
proliferation of wild-type b-cells (from 1% to 3,5%) but this
increase was absent from the E1-DN mouse islets correlating with
the in vivo results (Fig 1 B).
Quantitative morphometry of islets during pregnancy.
In addition to b-cell proliferation, some studies report that also
the number of islets increases during pregnancy. To investigate the
effect of EGFR signaling on the possible formation of new islets
during pregnancy we analyzed the number of islets per pancreatic
area from non-pregnant mice and at gestational day 14.5
(GD14.5). The wild-type mice had more small islets than the
E1-DN mice in both pregnant and non-pregnant pancreata
(Fig 1C–D). Additionally, there was a trend for increased islet
density during pregnancy in both wild-type and E1-DN mice,
especially in small islets (Fig 1C–D) suggestive of islet neogenesis.
When the islet density was multiplied by pancreatic weight, there
was a significant increase in the number small islets in the wild-
type mice (Fig 1E).
In classical two-dimensional stereological analysis the whole
pancreas is sectioned and examined at repeated intervals to cover
the entire depth of the pancreas. However, the quantification of
the total islet number is challenging. New three-dimensional (3D)
methods enable the quantification of insulin-positive volume from
the whole pancreas, providing also information about the number
of individual islets in addition to total insulin-positive volume. To
further clarify the possible formation of new islets during
pregnancy and to study the dynamics of b-cell mass changes in
3D, we applied the three-dimensional OPT method to wild-type
control and pregnant mice. Two time-points were chosen:
gestational day 13.5 (GD13.5), when b-cell proliferation has been
shown to peak, and day 18.5 (GD18.5) when the b-cell mass is at
its highest [13].
With the three-dimensional approach, we detected a 1.2-fold
increase in the insulin-positive volume at GD13.5 and a 1.4-fold
increase by GD18.5 (Fig 2 A–D, Movie S1). Interestingly, the islet
number increased by GD13.5 (from 680 to 1134 islets per
pancreas, p,0.001) but remained steady from GD13.5 to GD18.5
(1134 vs 1054 islets, ns) (Fig 2E). The increase in islet number was
mainly due to increase in the smaller islets (0–10006103 mm3;
Fig 2G). However, large islets accounted for most of the total b-cell
mass and also during pregnancy, the absolute increase in the b-cell
volume was mostly due to the increased volume of the large
(.56106 mm3) islets (Fig 2F).
In order to directly compare the islet number and beta cell mass
results between the OPT and classical morphometric 2D method,
we sectioned the same pancreata that were analyzed by OPT and
subjected them to the 2D analysis. This method revealed a 34%
increase in insulin-positive volume by GD13.5 and a 53% increase
by GD18.5 (Fig 3 A–B). The proportional increase in small islets
by GD13.5 was less than obtained with OPT (Fig 3 C–E).
However, by GD18.5 the number of small islets had increased
significantly also with this method (Fig 3D–F).
Survivin expression is not increased in E1-DN islets
during pregnancy
Next we investigated why the E1-DN islets do not respond to
lactogenic stimulation. We isolated islets from maternal pancreata
at GD13.5 from wild-type and E1-DN mice and analyzed the
expression of selected genes. Survivin has been shown to be
upregulated during pregnancy and is a known target for EGFR
signaling [6,22]. Interestingly, survivin (Birc5) expression was
highly (up to five-fold) upregulated in wild-type islets during
pregnancy, but this increase was lacking from the E1-DN islets
(Fig 4A). Additionally we analyzed expression of the serotonin-
synthesizing enzymes Tph1 and Tph2 and the Serotonin receptor
Htr2B, which all have been shown to be involved in the regulation
of gestational b-cell proliferation [7,9]. Tph1 and Tph2 were
upregulated at a similar level in both the wild-type and E1-DN
islets (Fig 4B–C). Furthermore, there was no difference in Htr2B
expression level between the groups (Fig 4 D). We also analyzed
the expression of FoxM1, which has been shown to be required for
beta cell proliferation during pregnancy [10]. No difference could
be detected in FoxM1 expression between the genotypes (Fig 4 E).
The human EGFR transgene was abundantly expressed in the E1-
DN mice as expected (data not shown), while the endogenous Egfr
expression did not significantly change between the genotypes or
during pregnancy (Fig 4F). Finally, there was no difference in the
Prlr expression during pregnancy between the genotypes (Fig 4 G).
The difference in survivin expression was confirmed at protein
level by immunohistochemistry, since survivin-like immunoreac-
tivity was clearly detectable in the b-cells of the pregnant wild-type
mice, while only a very faint signal was obtained in the islets of the
EGFR in b-Cells during Pregnancy
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pregnant E1-DN mice (Fig 5 A–H). Preabsorption of the anti-
survivin with a blocking peptide abolished completely the
fluorescence serving as a specificity control.
Survivin upregulation depends on EGFR, mTOR and MEK.
To determine whether PL stimulation induced survivin
upregulation could be blocked by EGFR inhibitor in vitro and
which signaling pathways are involved, we isolated pancreatic
islets and stimulated them with PL with or without EGFR
inhibitor gefitinib or MEK inhibitor PD0325901 or mTOR
inhibitor rapamycin for 4 days. PL induced a 2.3-fold increase in
survivin mRNA expression and this increase was blocked by
gefitinib and by MEK inhibitor as well as by rapamycin (Fig 6 A).
On the contrary, PL-induced Tph1 upregulation, which is
stimulated by JAK2/STAT5 pathway, could not be blocked by
gefinitib nor MEK inhibitor, as expected (Fig 6 B). PL-induced
Tph1 upregulation was reduced by rapamycin when compared to
PL alone, but the expression level remained significantly higher
than in the controls (Fig 6B).
Discussion
EGFR signaling has been linked to both b-cell replication and
differentiation [23–26]. We have previously shown that the EGFR
is crucial in pregnancy-induced b-cell mass expansion, primarily
due to inadequate b-cell proliferation of the maternal islets [12]. In
this study we aimed to investigate in more detail the molecular
mechanism linking EGFR signaling with beta cell proliferation
during pregnancy. We took advantage of the beta-cell specific
EGFR dominant negative mouse model which we created earlier
(the E1-DN mice) [19]. The heterozygous mice, which were used
in these experiments, are euglycemic under normal physiological
Figure 1. E1-DN mice do not increase b-cell mass during pregnancy. A: The b-cell mass of wild-type mice increases during pregnancy at
GD14.5. There is no difference between groups of E1-DN mice, n = 8–13. B: Isolated islets from wild-type (WT) and E1-DN (E1) female virgin mice were
cultured for 96 h either with PL 500 ng/ml or in control media (con). BrdU was added to the media for the last 48 h. Quantification of proliferative b-
cells, n = 3 in each group. C: Total number of islets per pancreatic area from WT and E1-DN (E1) control and pregnant gestational day 14.5 (GD14.5)
mice, n = 4–6 per group. D: The distribution of islet sizes relative to total pancreatic area. Islets were classified into small ,12076 mm2, medium
12076–35033 mm2 and large islets.35033 mm2 from wild-type (WT) and E1-DN (E1) control (con) and gestational day 14.5 (GD14.5) pancreata, n = 4–
6 per group. E: The islet size distribution corrected for pancreatic weight. AU, arbitrary unit. Bars represent the mean 6SEM for each group. *p,0.05,
**p,0.01,***p,0.001, ****p,0.0001 ns = no statistical significance.
doi:10.1371/journal.pone.0093651.g001
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Figure 2. OPT analysis of insulin-positive volume and islet number during pregnancy. A–C: Isosurface rendered OPT images of insulin
labeled (red) representative pancreata from control (A), gestational day 13.5 (GD13.5) (B) and gestational day 18.5 (GD18.5) (C) female mice. The
pancreas outline is based on autofluorescence of the tissue. D: Graph illustrating the average insulin-positive volume in control (white), GD13.5 (gray)
and GD18.5 (black) pancreata, n = 7–8 per group. E: Graph illustrating the average number of islets per pancreas in control (white), GD13.5 (gray) and
GD18.5 (black) pancreata, n = 7–8 per group. F–G: The distribution of islet sizes (G) and contribution to total islet volume (F) n = 7–8 per group. Islets
were classified into small 0–1000 um36103, intermediate 1000–5000 um36103 and large islets .5000 um36103 from control (white), GD13.5 (gray)
and GD18.5 (black) pancreata. Bars represent the mean 6SEM for each group. *p,0.05, **p,0.01, ***p,0.001 ns = no statistical significance.
doi:10.1371/journal.pone.0093651.g002
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conditions. However, the mice are unable to increase their beta
cell mass during pregnancy and become hyperglycemic [12].
In addition to direct ligand binding, the ErbB receptors have
been shown to act as signal integrators, as they can act as targets of
signaling events emanating from other receptors [27,28]. Since
lactogens are the most important stimulators of b-cell mass
expansion during pregnancy, we hypothesized that Prl-R signaling
acts partially through EGFR. The involvement of EGFR in Prl-R
signaling is supported by previous findings of the interplay
between EGF and Prl in breast cancer cells. Prl induces threonine
phosphorylation of EGFR through ERK pathway and synergis-
tically augments EGF signaling by inhibiting the downregulation
of activated EGFR [29,30]. In our study we show that the PL-
induced b-cell proliferation was affected by downregulation of
EGFR signaling in murine islets. When E1 islets were stimulated
with PL in vitro, the b-cells could not increase their proliferation
unlike the wild-type b-cells.
In addition to increased b-cell proliferation, several studies have
reported formation of new islets during pregnancy [3,15,16]. On
the other hand, some studies argue against islet neogenesis during
pregnancy [14]. To explore whether EGFR signaling also affects
new islet formation and whether new islets actually do form, we
analyzed islet number and islet size distribution from wild-type
and E1-DN pancreata. Our data from 2D analysis implied that
new islets were formed during pregnancy. This was further
analyzed with the 3D OPT method. The results revealed that b-
cell mass increased by 1.2-fold at GD13.5 and continued to
expand until late pregnancy up to 1.4-fold when compared with
Figure 3. Validation of OPT method by 2D morphometrical analysis. The same pancreata that were analyzed by OPT were sectioned and
analyzed with routine methods. A: Insulin positive area per total pancreatic area. B: Insulin positive surface area per pancreatic area multiplied by total
pancreatic volume. C: Number of islets per pancreatic area multiplied by total pancreatic volume. D: Islets were classified into small ,12076 mm2,
medium 12076–35033 mm2 and large islets .35033 mm2 and the distribution was calculated per total surface area and further multiplied by total
pancreatic weight. AU, arbitrary unit. Bars represent the mean 6SEM for each group, n = 6–8. *p,0.05, **p,0.01. E–F: Representative images of
insulin immunohistochemistry (red) from non-pregnant (E) and pregnant GD18.5 (F) pancreas.
doi:10.1371/journal.pone.0093651.g003
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the non-pregnant controls. Since OPT is a novel method and has
not been previously used to study beta cell mass adaptation during
pregnancy, we validated the method by doing also a 2D analysis
from the same pancreata. In the 2D analysis the total beta cell
volume was increased by 34% at GD 13.5 and by 53% at G18.5.
These results are in line with the OPT results, although the
magnitude of beta cell mass increase is slightly smaller with the
OPT.
Interestingly, we could detect a prominent increase in the
number of islets during pregnancy in the wild-type mice with both
methods suggestive of islet neogenesis. However, the majority of
the increase in islet volume in our data is due to increased volume
of the largest islets, rather than by formation of new islets during
pregnancy. Major weakness of the OPT analysis is that its
detection limit excludes very small islets, i.e. less than 56103 um3
in size. Consequently, single b-cell or small b-cell clusters that fall
below OPT detection limit may proliferate and increase in size
above the detection limit and probably account for a part of the
‘‘new’’ islets. However, we rarely detect small islets with
proliferating b-cells and the absolute increase in our study was
up to 400 islets, making it unlikely that all the new islets would
have resulted from the proliferation of existing small clusters.
Furthermore, we did detect increased number of small islets also
with the 2D morphometrical analysis. Lineage tracing approaches
Figure 4. Reduced EGFR signaling leads to decreased survivin expression in islets during pregnancy in mice. A–G: Islets were isolated
from wild-type (WT) and E1-DN (E1) virgin (con) and gestational day 13.5 (GD13.5) mice and RT-qPCR performed. Graphs are showing the relative
mRNA level of survivin (A), Tph1 (B), Tph2 (C), serotonin receptor Htr2B (D), FoxM1 (E), endogenous mouse Egfr (F) and prolactin receptor (G) n = 4–5
per group. *p,0.05, **p,0.01, ns = no statistical significance.
doi:10.1371/journal.pone.0093651.g004
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would be needed to confirm whether islet neogenesis actually
occurs and from what cell type.
To elucidate the molecular mechanisms through which EGFR
affects pregnancy-induced b-cell proliferation we isolated islets
from wild-type and E1-DN pregnant and control mice and studied
gene expression of selected genes (i.e. Htr2B, Tph1 and 2, Birc5,
FoxM1 and Prlr). During pregnancy the b-cells start to synthesize
serotonin, which then acts in a paracrine-autocrine fashion
through Htr2B to stimulate b-cell proliferation [9]. It has been
shown that blocking Htr2B signaling during pregnancy also blocks
b-cell mass expansion. However, there are controversial results
concerning Htr2B expression levels during pregnancy, as Kim et al
report that the receptor expression increases during pregnancy [9],
while Schraenen et al did not see this [7]. Our results are in line
with the latter result, showing no major changes in Htr2B
expression during pregnancy.
The major difference between wild-type and E1-DN mice was
that survivin was strongly upregulated during pregnancy in wild-
type islets, while no upregulation was seen in the E1-DN islets.
Survivin acts as an inhibitor of apoptosis that is also involved in
cell division. It can inhibit both the intrinsic and extrinsic apoptosis
pathways by blocking the activity of several caspase proteins
[31,32]. In addition, survivin forms complexes with chromosomal
passenger proteins including aurora B kinase, INCENP and
Borealin to regulate cell division [32]. In pancreas survivin is
expressed during embryonic period throughout the pancreatic
epithelium, but becomes gradually restricted to pancreatic b-cells.
Survivin expression is very low in adult mouse islets but becomes
upregulated during pregnancy and after pancreatic duct ligation
[6,33]. Mice lacking survivin in b-cells develop insulin-deficient
diabetes after birth due to a failure of b-cell mass expansion
[34,35] and show defective b-cell mass expansion and proliferation
after pancreatic injury [33]. On the other hand, overexpression of
survivin does not induce b-cell proliferation but improves survival
of islet grafts [36].
EGFR signaling has been linked to survivin in many cancer
studies [37], and it has been shown that EGFR activates the
PI3K/Akt pathway leading to upregulation of HIF-1alpha which
subsequently activates survivin gene expression by binding to its
promoter region [22]. In our study, survivin expression was
upregulated during pregnancy in the maternal rodent islets and
this increase was dependent of intact EGFR signaling, since no
survivin upregulation was evident in the E1-DN pregnant islets.
Importantly, we also detected survivin at the protein level only
from wild-type islets during pregnancy, not from E1-DN pregnant
pancreata.
In vitro stimulation of pancreatic islets with PL resulted in
increased survivin expression. This effect was blocked by the
Figure 5. Survivin immunoreactivity is detectable in islets of pregnant wild-type but not E1-DN mice. A–H: Double
immunohistochemistry for survivin (green) and insulin (red) from wild-type non-pregnant (A), E1-DN non-pregnant (B), wild-type pregnant
GD14.5 (C) and E1-DN pregnant GD14.5 (D) mouse. Scale bar 200 mm. E: Magnification of squared area in C. F: Magnification of squared area in D. G:
Negative control from wild-type pregnant mouse pancreas with blocking peptide. Scale bar 200 mm. H: Magnification of squared area in G.
doi:10.1371/journal.pone.0093651.g005
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tyrosine kinase inhibitor of EGFR, confirming that EGFR
activation is needed for PL-induced survivin upregulation. EGFR
activation in pancreatic beta cells leads to activation of MAPK and
PI3K pathways [26,38,39]. Recently it was demonstrated that
mTOR participates in EGFR signaling in beta cells during glucose
and intralipid infusion induced insulin resistance, where the
compensatory beta cell mass expansion was stimulated via the
EGFR-PI3K-mTOR pathway [40]. To test which signaling
pathways participate in PL-induced survivin expression, we used
the MEK inhibitor PD 0325901 and the mTOR inhibitor
rapamycin. Both of these inhibitors similarly prevented the PL-
induced upregulation of survivin, implying that joint activation of
Figure 6. PL-induced survivin upregulation is dependent of EGFR, mTOR and MEK. A–B: Islets were isolated from wild-type mice,
stimulated with or without PL (500 ng/ml), gefitinib (2 mM), rapamycin (10 nM), MEK inhibitor PD0325901 (0,5 mM) or EGF (50 ng/ml) and BTC (50 ng/
ml) for 96 h and RT-qPCR performed. Graph is showing the relative mRNA level of survivin (A) and Tph1 (B). n = 6–9 per group. Bars represent the
mean 6SEM for each group. *p,0.05, **p,0.01 ***p,0.001. C: Proposed model for PL-induced survivin upregulation. Prl-R activation leads to
transactivation of EGFR, which activates MAPK and PI3K-Akt-mTOR pathways, that together stimulate survivin gene expression.
doi:10.1371/journal.pone.0093651.g006
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both mTOR and MAPK pathway is needed for survivin
upregulation. Importantly, these inhibitors did not have a major
effect on Tph1, a known JAK2/STAT5 target. Collectively, these
results allow to propose a signaling cascade illustrated in Fig 6C,
highlighting the transactivation of EGFR as an important
component in gestational beta-cell expansion triggered by Prl-R
activation.
In summary, we provide the first 3D-volumetric analysis of the
dynamics of b-cell mass expansion during murine pregnancy,
showing that the number of islets nearly doubles during
pregnancy. In addition, we show that EGFR signaling is involved
in pregnancy- and lactogen-induced b-cell proliferation and that
the mechanism involves survivin expression. Our findings further
elucidate the physiological adaptation of b-cell mass to pregnancy.
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